Business Description
Equillium is a US-based biotechnology company focused on developing treatments for serious immune system disorders that currently have few effective options. Its primary drug candidate, Itolizumab, works by targeting a specific protein involved in harmful immune responses and is being tested across multiple conditions, including graft-versus-host disease, lupus, and ulcerative colitis. The company also has a second experimental therapy aimed at certain immune-driven cancers affecting the skin. Founded in 2017 and based in La Jolla, California, Equillium works alongside Biocon SA under a licensing agreement to advance its lead treatment.
